Abstract
Background
We hypothesized that the survival benefit of external beam radiation therapy (EBRT) recorded in European low-volume metastatic prostate cancer (mPCA) patients, will apply to similar North American patients.
Methods
Newly diagnosed mPCa patients with M1a/b substages, treated with EBRT or no EBRT were abstracted from the Surveillance, Epidemiology, and End Results database (2004–2016). Kaplan–Meier plots and Cox-regression models targeted overall mortality (OM) and cancer specific-mortality (CSM) according to EBRT administration. M1 substages and PSA stratified analyses were performed. Internal validation relied on 2000 bootstrap resamples.
Results
Of 15,494 patients, 1156 (7.5%) were M1a vs 14,338 (92.5%) were M1b. PSA at diagnosis ≤10.0 ng/ml was recorded in 1463 (9.4%) patients. In all 15,494 patients, EBRT did not affect OM (hazard ratio [HR] 1.0; p = 0.5). However, in M1a patients and M1b patients with PSA ≤ 10.0 ng/ml EBRT was associated with lower OM (HR 0.73, CI 0.62–0.86; p < 0.001) but not in M1b patients with PSA > 10.0 ng/ml. The PSA cut-off of ≤ 10.0 ng/ml represented the most statistically significant cut-off for OM prediction in M1b patients. Moreover, internal validation with 2000 bootstrap resamples confirmed these findings. Finally, all results were virtually the same, when CSM represented the endpoint of interest.
Conclusions
We validated the OM reduction associated with EBRT in M1a and M1b patients with PSA ≤ 10.0 ng/ml but not in M1b patients with PSA > 10.0 ng/ml. In consequence, it appears that a smaller subset of North American mPCa patients benefit of EBRT than originally reported in European patients. Further North American validation studies are essential.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mohler JL, Higano CS, Pugh TJ. NCCN Guidelines index table of contents discussion. Prostate Cancer. Version 4.2019, 2019;166:MS-22.
Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. https://doi.org/10.1056/NEJMoa1503747.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32486-3/abstract.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–8. https://www.europeanurology.com/article/S0302-2838(18)30658-4/abstract.
Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, et al. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol. 2019;38:1459–64.
Sooriakumaran P, Karnes RJ, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. https://mayoclinic.pure.elsevier.com/en/publications/a-multi-institutional-analysis-of-perioperative-outcomes-in-106-m.
Pompe RS, Tilki D, Preisser F, Leyh-Bannurah S-R, Bandini M, Marchioni M, et al. Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages. Prostate. 2018;78:753–7. https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.23519.
About the SEER Program [Internet]. SEER. [cited 2019 Sep 11]. https://seer.cancer.gov/about/overview.html.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471–4. https://doi.org/10.1245/s10434-010-0985-4.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60. https://doi.org/10.1056/NEJMoa1704174.
Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2012. http://www.R-project.org. 2018.
Publications and Resources | UICC [Internet]. [cited 2020 Jan 22]. https://www.uicc.org/resources/tnm/publications-resources.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74. https://jamanetwork.com/journals/jama/fullarticle/187980.
Ali SA, Hoyle A, James ND, Parker C, Brawley C, Attard G. et al. Benefit of prostate radiotherapy for patients with lymph node only or <4 bone metastasis and no visceral metastases: exploratory analyses of metastatic site and number in the STAMPEDE “M1_RT comparison.” Ann Oncol.2019;30 Suppl 5:v325–55. https://doi.org/10.1093/annonc/mdz248https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Benefit-of-prostate-radiotherapy-for-patients-with-lymph-node-only-or-4-bone-metastasis-and-no-visceral-metastases-Exploratory-analyses-of-metastatic-site-and-number-in-the-STAMPEDE-M1_RT-comparison.
Freedland SJ, Terris MK, Platz EA, Presti JC. Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology. 2005;66:108–13. http://www.sciencedirect.com/science/article/pii/S0090429505001718.
Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy11The opinions and assertions contained herein are the views of the authors and are not to be construed as reflecting the views of the U.S. Navy, Army, Air Force, or Department of Defense. Urology. 2001;58(Nov):723–8. http://www.sciencedirect.com/science/article/pii/S0090429501013735.
Gallina A, Karakiewicz PI, Hutterer GC, Chun FK-H, Briganti A, Walz J, et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer. 2007;121:791–5. https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.22730.
Lughezzani G, Budäus L, Isbarn H, Sun M, Perrotte P, Haese A, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol. 2010;57:562–8.
Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. Int Urol Nephrol. 2019;52:59–66.
Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88–95.
Dell’Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah S-R, et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2016;96:1037–45.
Author information
Authors and Affiliations
Contributions
Conceptualization: LFS, PIK. Data curation: LFS, ZT formal analysis: LFS, ZT. Funding acquisition: ---Investigation: LFS, MD, CC-R, LN, and MM. Methodology: LFS, project administration resources. SEER database software R system supervision: PIK validation: ZT, PIK, DT, TS, AB, and FS.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Stolzenbach, L.F., Deuker, M., Collà-Ruvolo, C. et al. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer Prostatic Dis 24, 253–260 (2021). https://doi.org/10.1038/s41391-020-00276-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-020-00276-2